What certifications should procurement teams require before onboarding a CBD Oil Market supplier?

Require EU-GMP or NSF/ANSI 455 certification, ISO 17025 accredited batch testing, and a documented chain-of-custody from cultivar to finished lot. Suppliers unable to produce all three typically rely on third-party tolling they do not control [1][8]. Read More

How does insurance and liability coverage work for CBD Oil Market operators?

Most general liability policies exclude cannabinoid products, requiring specialty carriers who price 30–60% above standard rates. Product recall coverage is often written separately and remains difficult to obtain for ingestibles [17]. Read More

Are isolate, broad-spectrum, and full-spectrum inputs interchangeable in formulation?

No. Isolate offers analytical simplicity and zero THC risk, while full-spectrum retains minor cannabinoids and terpenes that alter effect profile. Switching between them changes stability, taste, and regulatory classification [9]. Read More

What intellectual property is actually defensible in the CBD Oil Market?

Plant variety protection on proprietary cultivars, formulation patents on delivery systems, and trade secrets around extraction parameters. Molecule-level claims are unavailable because cannabidiol itself is not patentable [10][15]. Read More

How should buyers evaluate contract manufacturers against in-house extraction?

Below roughly 15 tonnes of annual biomass throughput, tolling is almost always cheaper than owning a compliant line. In-house capacity makes sense only when formulation secrecy or supply security justifies the fixed cost [11]. Read More

What sports and workplace testing risks accompany cannabidiol use?

Cannabidiol is not prohibited by the World Anti-Doping Agency, but trace THC in broad-spectrum or full-spectrum products can trigger positive screens. Athletes and safety-sensitive employees should specify certified isolate formulations [22]. Read More

Which distribution partnerships create the most durable margin?

Pharmacy and veterinary clinic channels lock in repeat prescribing relationships that mass retail cannot replicate. Both demand clinical documentation upfront but resist the price erosion typical of e-commerce [6][13]. Read More

CBD Oil Market (2026 - 2035)

ID: MRFR/HC/5886-CR 117 Pages Vikita Thakur Last Updated: September 15, 2026

CBD Oil (Cannabidiol Oil) Market Research Report By Application (Therapeutic, Cosmetics, Food and Beverages, Vaping, Nutraceuticals), By Source (Hemp-Derived, Marijuana-Derived), By Formulation (Oil, Tinctures, Capsules, Edibles, Topicals), By End Use (Pharmaceuticals, Personal Care Products, Food Industry, Wellness Centers) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

CBD Oil Market

Market Size

Forecast Period2026-2035

CAGR (2026-2035)12.6%

2025 Market SizeUSD 2.76 Billion

2035 Market SizeUSD 9.04 Billion

Key Players

Jazz Pharmaceuticals

Charlotte's Web Holdings

Canopy Growth Corporation

Tilray Brands

cbdMD Inc.

CV Sciences

Trends

Regulatory Harmonisation and the GMP Threshold
Clinical Evidence Moves From Anecdote to Endpoint
Formulation Science Widens the Occasion

Opportunities

Prescription-Adjacent Medical Channels
Veterinary and Companion-Animal Formulations
Emerging-Market Cultivation and Export Arbitrage

Summary Table of Contents Segmentation Methodology Download PDF

1 Market Overview |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Market Summary & Key Report Takeaways |
1. 2.1 By Source Type |
2. 2.2 By Product Form and Sales Type |
3. 2.3 By Geography
3 Global Market Size & Forecast (2021–2035) |
1. 3.1 Historical Market Size (2021–2025) |
2. 3.2 Current & Forecast Market Size (2026–2035) |
3. 3.3 Market Size by Revenue (USD Billion) |
4. 3.4 Year-over-Year Growth Analysis
4 Market Drivers Analysis |
1. 4.1 Regulatory Harmonisation and the GMP Threshold |
2. 4.2 Clinical Evidence Moves From Anecdote to Endpoint |
3. 4.3 Formulation Science Widens the Occasion |
4. 4.4 Cost Deflation Reinvested Into Category Building
5 Market Restraints Analysis |
1. 5.1 The Regulatory Vacuum in the United States |
2. 5.2 Europe's Authorisation Bottleneck |
3. 5.3 Consistency and Consumer Trust
6 Market Opportunity Analysis |
1. 6.1 Prescription-Adjacent Medical Channels |
2. 6.2 Veterinary and Companion-Animal Formulations |
3. 6.3 Emerging-Market Cultivation and Export Arbitrage |
4. 6.4 Data Monetisation Through Outcomes Registries |
5. 6.5 Cosmetic Actives and Dermatology Crossover |
6. 6.6 Industry Value Chain Analysis |
7. 6.7 Porter's Five Forces Analysis
7 Regional Analysis |
1. 7.1 North America | |
  1. 7.1.1 US | |
  2. 7.1.2 Canada | |
  3. 7.1.3 Mexico |
2. 7.2 Europe | |
  1. 7.2.1 Germany | |
  2. 7.2.2 UK | |
  3. 7.2.3 France | |
  4. 7.2.4 Italy | |
  5. 7.2.5 Spain | |
  6. 7.2.6 Nordic Countries | |
  7. 7.2.7 Russia | |
  8. 7.2.8 Rest of Europe |
3. 7.3 Asia-Pacific | |
  1. 7.3.1 China | |
  2. 7.3.2 India | |
  3. 7.3.3 Japan | |
  4. 7.3.4 South Korea | |
  5. 7.3.5 ASEAN | |
  6. 7.3.6 Rest of Asia-Pacific |
4. 7.4 South America | |
  1. 7.4.1 Brazil | |
  2. 7.4.2 Argentina | |
  3. 7.4.3 Rest of South America |
5. 7.5 Middle East & Africa | |
  1. 7.5.1 Saudi Arabia | |
  2. 7.5.2 UAE | |
  3. 7.5.3 South Africa | |
  4. 7.5.4 Egypt | |
  5. 7.5.5 Rest of Middle East & Africa
8 Future Outlook (2026–2035) |
1. 8.1 Precision Dosing and Digital Adherence |
2. 8.2 Consolidation and the Return of Pricing Power |
3. 8.3 Cannabinoid Portfolio Diversification |
4. 8.4 Sustainability and Supply-Chain Traceability
9 Segmentation Analysis |
1. 9.1 By Source Type | |
  1. 9.1.1 Hemp-Derived | |
  2. 9.1.2 Marijuana-Derived |
2. 9.2 By Product Form | |
  1. 9.2.1 Oils and Tinctures | |
  2. 9.2.2 Capsules and Softgels | |
  3. 9.2.3 Edibles and Gummies | |
  4. 9.2.4 Topicals and Cosmetics | |
  5. 9.2.5 Beverages | |
  6. 9.2.6 Others |
3. 9.3 By Sales Type | |
  1. 9.3.1 B2B | |
  2. 9.3.2 B2C — Offline Retail Pharmacies | |
  3. 9.3.3 B2C — Online and Direct |
4. 9.4 By End-Use Sector | |
  1. 9.4.1 Medical and Pharmaceuticals | |
  2. 9.4.2 Cosmetics and Beauty | |
  3. 9.4.3 Food and Beverages | |
  4. 9.4.4 Veterinary and Pet Products | |
  5. 9.4.5 Others
10 Competitive Landscape |
1. 10.1 Market Share Analysis (2026) |
2. 10.2 Competitive Benchmarking Matrix |
3. 10.3 Company Profiles | |
  1. 10.3.1 Jazz Pharmaceuticals | |
  2. 10.3.2 Charlotte's Web Holdings | |
  3. 10.3.3 Canopy Growth Corporation | |
  4. 10.3.4 Tilray Brands | |
  5. 10.3.5 cbdMD Inc. | |
  6. 10.3.6 CV Sciences | |
  7. 10.3.7 Aurora Cannabis | |
  8. 10.3.8 Medterra CBD | |
  9. 10.3.9 Endoca | |
  10. 10.3.10 Elixinol Wellness | |
  11. 10.3.11 NuLeaf Naturals
11 Recent Developments & News
12 Report Scope & Methodology |
1. 12.1 Study Period & Base Year |
2. 12.2 Valuation Currency & Conversion Assumptions |
3. 12.3 Abbreviations
13 Detailed Sources & Citations
14 Frequently Asked Questions
15 LIST OF TABLES |
TABLE 1 Global CBD Oil Market Size & Forecast, by Revenue (USD Billion), 2021–2035 |
TABLE 2 Global CBD Oil Market – Year-over-Year Growth Analysis, 2021–2035 |
TABLE 3 Market Driver Impact Analysis – Impact Weighting, Geography and Timeline |
TABLE 4 Market Restraint Impact Analysis – Impact Weighting, Geography and Timeline |
TABLE 5 Global CBD Oil Market Size, by Region, 2021–2035 (USD Billion) |
TABLE 6 North America CBD Oil Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 7 Europe CBD Oil Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 8 Asia-Pacific CBD Oil Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 9 South America CBD Oil Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 10 Middle East & Africa CBD Oil Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 11 Global CBD Oil Market Size, by Source Type, 2021–2035 (USD Billion) |
TABLE 12 Global CBD Oil Market Size, by Product Form, 2021–2035 (USD Billion) |
TABLE 13 Global CBD Oil Market Size, by Sales Type, 2021–2035 (USD Billion) |
TABLE 14 Global CBD Oil Market Size, by End-Use Sector, 2021–2035 (USD Billion) |
TABLE 15 North America CBD Oil Market Size, by Source Type and Product Form, 2021–2035 (USD Billion) |
TABLE 16 Europe CBD Oil Market Size, by Sales Type and End-Use Sector, 2021–2035 (USD Billion) |
TABLE 17 Asia-Pacific CBD Oil Market Size, by Product Form and End-Use Sector, 2021–2035 (USD Billion) |
TABLE 18 South America CBD Oil Market Size, by Source Type and Sales Type, 2021–2035 (USD Billion) |
TABLE 19 Middle East & Africa CBD Oil Market Size, by Product Form and End-Use Sector, 2021–2035 (USD Billion) |
TABLE 20 Competitive Benchmarking Matrix – Global CBD Oil Market, 2026 |
TABLE 21 Company Profiles – Key Players, Global CBD Oil Market |
TABLE 22 Recent Developments & Strategic Announcements, 2023–2025 |
TABLE 23 Report Scope & Methodology Summary |
TABLE 24 Detailed Sources and Citations Index
16 LIST OF FIGURES |
FIGURE 1 Global CBD Oil Market Dynamics – Drivers, Restraints and Opportunities Map |
FIGURE 2 Industry Value Chain Analysis – Cultivation to Finished Formulation |
FIGURE 3 Porter's Five Forces Analysis – Global CBD Oil Market |
FIGURE 4 Global Market Size Trend and Forecast Curve, 2021–2035 (USD Billion) |
FIGURE 5 Year-over-Year Growth Trajectory, 2022–2035 (%) |
FIGURE 6 Market Share by Source Type, 2025 vs 2035 (%) |
FIGURE 7 Market Share by Product Form, 2025 (%) |
FIGURE 8 Market Share by Sales Type, 2025 (%) |
FIGURE 9 Market Share by End-Use Sector, 2025 vs 2035 (%) |
FIGURE 10 Regional Revenue Share Distribution, 2025 (%) |
FIGURE 11 Regional CAGR Comparison, 2026–2035 (%) |
FIGURE 12 North America Country-Level Revenue Split, 2025 (%) |
FIGURE 13 Europe Country-Level Revenue Split, 2025 (%) |
FIGURE 14 Asia-Pacific Country-Level Revenue Split, 2025 (%) |
FIGURE 15 Competitive Landscape – Estimated Revenue Share Bands, 2026 |
FIGURE 16 Strategic Positioning Matrix – Scale vs Regulatory Certification Depth |
FIGURE 17 Cannabinoid Input Price Index Trend, 2021–2025 |
FIGURE 18 Fastest-Growing Segment Comparison, 2026–2035 CAGR (%)

Certified Researchers

Enquiry

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
By Source Type	Hemp-Derived; Marijuana-Derived	Hemp-Derived	Marijuana-Derived
By Product Form	Oils and Tinctures; Capsules and Softgels; Edibles and Gummies; Topicals and Cosmetics; Beverages; Others	Oils and Tinctures	Edibles and Gummies
By Sales Type	B2B; B2C (Offline Retail Pharmacies); B2C (Online and Direct)	B2B	B2C (Offline Retail Pharmacies)
By End-Use Sector	Medical and Pharmaceuticals; Cosmetics and Beauty; Food and Beverages; Veterinary and Pet Products; Others	Medical and Pharmaceuticals	Veterinary and Pet Products
By Geography	North America; Europe; Asia-Pacific; South America; Middle East & Africa	North America	Asia-Pacific

Market Segmentation Overview

By Source Type

Sub-Segment	Key Trend
Hemp-Derived	Cross-border tradability under sub-0.3% THC thresholds keeps hemp the default input for multi-region contract manufacturers
Marijuana-Derived	Dispensary channels support premium full-plant formulations as medical and adult-use programmes widen

Source classification determines almost everything downstream — customs treatment, permissible claims, retail channel access, and testing burden. Operators increasingly maintain parallel supply chains rather than choosing one, allowing a single brand to serve pharmacy, mass retail, and dispensary channels without reformulating.

By Product Form

Sub-Segment	Key Trend
Oils and Tinctures	Sublingual dosing precision retains loyal experienced users despite convenience trade-offs
Capsules and Softgels	Familiar supplement format easing pharmacy and mass-retail listing decisions
Edibles and Gummies	Taste masking removes the primary barrier to first-time trial
Topicals and Cosmetics	Premium skincare positioning where ingredient cost is a small fraction of shelf price
Beverages	Nano-emulsion stability improvements finally enabling ambient-shelf distribution
Others	Vapes, transdermal patches and specialty delivery devices

Format economics diverge sharply. Tinctures carry the highest gross margin per millilitre but the slowest new-user acquisition; gummies invert both. Beverage launches remain the highest-risk category because shelf-life failure destroys distributor relationships that take years to build.

By Sales Type

Sub-Segment	Key Trend
B2B	Concentrated GMP-certified processors supply hundreds of downstream labels
B2C — Offline Retail Pharmacies	Pharmacist-mediated recommendation drives conversion and repeat purchase
B2C — Online and Direct	Subscription models capture full margin but face advertising restrictions

Channel structure hides where power actually sits. Consumer-facing brands compete visibly on price and packaging while a small tier of certified processors sets input cost for the entire category, an arrangement that consolidation is likely to formalise through vertical integration.

By End-Use Sector

Sub-Segment	Key Trend
Medical and Pharmaceuticals	Prescription indications set the evidentiary benchmark other sectors borrow from
Cosmetics and Beauty	Dermatological research into receptor modulation supports premium claims
Food and Beverages	Functional wellness occasions expanding as bioavailability improves
Veterinary and Pet Products	Species-specific pharmacokinetic dossiers becoming a competitive differentiator
Others	Industrial, research and institutional applications

End-use concentration in medical applications reflects where reimbursement exists rather than where consumer interest is greatest. Veterinary demand grows fastest precisely because it sits outside human-health regulatory scrutiny while benefiting from the same underlying clinical literature.

By Region

Sub-Segment	Key Trend
North America	Federal-state regulatory divergence constrains national retail assortment
Europe	Novel-food dossier position functions as a tradeable competitive asset
Asia-Pacific	Japanese statutory revision triggering a broader regional liberalisation cycle
South America	Low-cost cultivation origins scaling export volumes to Europe and Asia
Middle East & Africa	Scheduling exemptions and contract farming creating narrow but growing access

Regional divergence is regulatory, not cultural. Consumer willingness to try cannabinoid wellness products is remarkably consistent across surveyed markets; what varies is whether a lawful, quality-assured product is available to buy when that interest surfaces.

Certified Researchers

Enquiry

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”